Analyst Ratings For Akebia Therapeutics (NASDAQ:AKBA)
Today, Mizuho reiterated its Buy rating on Akebia Therapeutics (NASDAQ:AKBA) with a price target of $24.00.
Some recent analyst ratings include
- 3/13/2018-Mizuho Reiterated Rating of Buy.
- 12/18/2017-Piper Jaffray Companies initiated coverage with a Overweight rating.
- 12/7/2017-BTIG Research initiated coverage with a Buy rating.
- 11/15/2017-HC Wainwright Reiterated Rating of Buy.
- 11/2/2017-Royal Bank of Canada Reiterated Rating of Hold.
- 6/30/2017-Aegis Reiterated Rating of Buy.
- 5/17/2017-Needham & Company LLC Reiterated Rating of Buy.
Recent Insider Trading Activity For Akebia Therapeutics (NASDAQ:AKBA)
Akebia Therapeutics (NASDAQ:AKBA) has insider ownership of 8.67% and institutional ownership of 71.23%.
- On 2/15/2018 Duane Nash, Director, sold 1,000 with an average share price of $14.62 per share and the total transaction amounting to $14,620.00.
- On 10/2/2017 Duane Nash, Director, sold 1,188 with an average share price of $19.64 per share and the total transaction amounting to $23,332.32.
- On 10/2/2017 Michel Dahan, SVP, sold 1,398 with an average share price of $19.64 per share and the total transaction amounting to $27,456.72.
- On 9/28/2017 Michel Dahan, SVP, sold 5,000 with an average share price of $19.30 per share and the total transaction amounting to $96,500.00.
- On 8/15/2017 Michel Dahan, SVP, sold 5,000 with an average share price of $15.00 per share and the total transaction amounting to $75,000.00.
- On 7/5/2017 Muneer A Satter, Director, bought 1,034,482 with an average share price of $14.50 per share and the total transaction amounting to $14,999,989.00.
- On 7/3/2017 Duane Nash, Director, sold 990 with an average share price of $14.27 per share and the total transaction amounting to $14,127.30.
Recent Trading Activity for Akebia Therapeutics (NASDAQ:AKBA)
Shares of Akebia Therapeutics closed the previous trading session at with 117556 shares trading hands.
